| CXCR4-directed theranostics in oncology and inflammation |
21 |
| F-18-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies |
14 |
| Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma |
14 |
| A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with (223)Radium-dichloride |
13 |
| F-18-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma |
12 |
| Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients |
12 |
| F-18-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival |
11 |
| Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma |
11 |
| Amyloid PET imaging in cardiac amyloidosis: a pilot study using F-18-flutemetamol positron emission tomography |
10 |
| Nuclear medicine practice in Japan: a report of the eighth nationwide survey in 2017 |
8 |
| 4-Borono-2-F-18-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research |
8 |
| Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds |
8 |
| SPECT and PET imaging in Alzheimer's disease |
8 |
| Prognostic implications of Cu-62-diacetyl-bis (N (4)-methylthiosemicarbazone) PET/CT in patients with glioma |
8 |
| Prognostic value of FDG-PET and DWI in breast cancer |
7 |
| Diagnosing polymyalgia rheumatica on F-18-FDG PET/CT: typical uptake patterns |
6 |
| Diagnostic performance of F-18-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma |
6 |
| Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis |
6 |
| Preliminary results of biodistribution and dosimetric analysis of [Ga-68] Ga-DOTA(ZOL): a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases |
6 |
| Phase I/IIa PET imaging study with (89)zirconium labeled anti-PSMA minibody for urological malignancies |
6 |
| Combining the radiomic features and traditional parameters of F-18-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery |
6 |
| Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT |
6 |
| Diagnostic performance of F-18-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy |
6 |
| Low levels of PSMA expression limit the utility of F-18-DCFPyL PET/CT for imaging urothelial carcinoma |
6 |
| Molecular imaging in musculoskeletal infections with Tc-99m-UBI 29-41 SPECT/CT |
6 |
| Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications |
6 |
| F-18-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings |
5 |
| Detectability of residual invasive bladder cancer in delayed F-18-FDG PET imaging with oral hydration using 500mL of water and voiding-refilling |
5 |
| 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients |
5 |
| Prognostic role of Delta MTV and Delta TLG in Burkitt lymphoma |
5 |
| A systematic review of the prognostic value of texture analysis in F-18-FDG PET in lung cancer |
5 |
| Preliminary clinical assessment of dynamic F-18-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer: a prospective study |
5 |
| Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site |
5 |
| Impact factors for the outcome of the first I-131 radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy |
4 |
| Diagnostic value of quantitative assessment of cardiac F-18-fluoro-2-deoxyglucose uptake in suspected cardiac sarcoidosis |
4 |
| Relationship between collateral circulation and myocardial viability of F-18-FDG PET/CT subtended by chronic total occluded coronary arteries |
4 |
| The role of (Ga-68)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax |
4 |
| How to recognize stent graft infection after endovascular aortic repair: the utility of 18F-FDG PET/CT in an infrequent but serious clinical setting |
4 |
| Evaluation of whole-body tumor burden with Ga-68-PSMA PET/CT in the biochemical recurrence of prostate cancer |
4 |
| Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas |
4 |
| Correlation of F-18-FDG and C-11-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas |
4 |
| Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2 |
4 |
| Association between carotid F-18-NaF and F-18-FDG uptake on PET/CT with ischemic vascular brain disease on MRI in patients with carotid artery disease |
4 |
| Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer |
4 |
| Factors affecting accuracy of S values and determination of time-integrated activity in clinical Lu-177 dosimetry |
4 |
| Diagnostic value of Tc-99m-ethambutol scintigraphy in tuberculosis: compared to microbiological and histopathological tests |
4 |
| Reproducibility of standardized uptake values of same-day randomized Ga-68-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients |
4 |
| The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival |
3 |
| Role of PET/MRI in oral cavity and oropharyngeal cancers based on the 8th edition of the AJCC cancer staging system: a pictorial essay |
3 |
| Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [F-18] FDOPA PET a prognostic factor in these patients? |
3 |
